Ming Lu1, Jing Gao, Xi-Cheng Wang, Lin Shen. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, PekingUniversitySchool of Oncology, BeijingCancerHospital& Institute, Beijing 100142, China.
Abstract
OBJECTIVE: Toevaluate the role of class III β-tubulin (TUBB3), thymidylate synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementing group 1 (ERCC1) in clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. METHODS: The clinical data and tumor specimens from 57 advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel (cohort 1, n=36) and capecitabine plus cisplatin (cohort 2, n=21) were retrospectively collected, and TUBB3, TS, TP, and ERCC1 expressions were detected by real-time quantitative PCR. The associations between expressions of biomarkers and response or survival were analyzed statistically. RESULTS: The median age of 57 patients was 57 years (range: 27-75 years) with 38 males and 19 females. Of all patients, the response rates of patients with high TP, low TP and high TS, low TS expressions were 57.1%, 27.6% (P=0.024), and 55.2%, 28.6% (P=0.042), respectively. Among cohort 1, the response rates and median overall survivals of patients with low and high TUBB3 expressions were 61.1% vs. 33.3% (P=0.095) and 13.8 months vs. 6.6 months (P=0.019), respectively; the response rate (87.5%) of patients with low TUBB3 and high TP expressions was higher than that (14.3%) of patients with high TUBB3 and low TP expressions (P=0.01). Among cohort 2, the response rates of patients with low ERCC1 and high ERCC1 expressions were 45.5% and 20.0% respectively (P=0.361). CONCLUSION: TUBB3, TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy. These results will be further confirmed in future large samples.
OBJECTIVE: Toevaluate the role of class III β-tubulin (TUBB3), thymidylate synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementing group 1 (ERCC1) in clinical outcome of advanced gastric cancerpatients receiving capecitabine plus paclitaxel or cisplatin. METHODS: The clinical data and tumor specimens from 57 advanced gastric cancerpatients receiving first-line capecitabine plus paclitaxel (cohort 1, n=36) and capecitabine plus cisplatin (cohort 2, n=21) were retrospectively collected, and TUBB3, TS, TP, and ERCC1 expressions were detected by real-time quantitative PCR. The associations between expressions of biomarkers and response or survival were analyzed statistically. RESULTS: The median age of 57 patients was 57 years (range: 27-75 years) with 38 males and 19 females. Of all patients, the response rates of patients with high TP, low TP and high TS, low TS expressions were 57.1%, 27.6% (P=0.024), and 55.2%, 28.6% (P=0.042), respectively. Among cohort 1, the response rates and median overall survivals of patients with low and high TUBB3 expressions were 61.1% vs. 33.3% (P=0.095) and 13.8 months vs. 6.6 months (P=0.019), respectively; the response rate (87.5%) of patients with low TUBB3 and high TP expressions was higher than that (14.3%) of patients with high TUBB3 and low TP expressions (P=0.01). Among cohort 2, the response rates of patients with low ERCC1 and high ERCC1 expressions were 45.5% and 20.0% respectively (P=0.361). CONCLUSION:TUBB3, TS and TP expressions could predict the response of advanced gastric cancerpatients receiving capecitabine-based and paclitaxel-based chemotherapy. These results will be further confirmed in future large samples.
Authors: F Puglisi; G G Cardellino; D Crivellari; C Di Loreto; M D Magri; A M Minisini; M Mansutti; C Andreetta; S Russo; D Lombardi; T Perin; G Damante; A Veronesi Journal: Ann Oncol Date: 2008-04-25 Impact factor: 32.976
Authors: Daniel Vallböhmer; Dong Yun Yang; Hidekazu Kuramochi; D Shimizu; Kathleen D Danenberg; Jan Lindebjerg; Jens Nederby Nielsen; Anders Jakobsen; Peter V Danenberg Journal: Int J Oncol Date: 2007-08 Impact factor: 5.650
Authors: Y-K Kang; W-K Kang; D-B Shin; J Chen; J Xiong; J Wang; M Lichinitser; Z Guan; R Khasanov; L Zheng; M Philco-Salas; T Suarez; J Santamaria; G Forster; P I McCloud Journal: Ann Oncol Date: 2009-01-19 Impact factor: 32.976
Authors: Rachel M Layman; Dafydd G Thomas; Kent A Griffith; Jeffrey B Smerage; Mark A Helvie; Marilyn A Roubidoux; Kathleen M Diehl; Lisa A Newman; Michael S Sabel; James A Hayman; Lori J Pierce; Daniel F Hayes; Anne F Schott Journal: Clin Cancer Res Date: 2007-07-15 Impact factor: 12.531
Authors: H J Kang; H M Chang; T W Kim; M-H Ryu; H-J Sohn; J H Yook; S T Oh; B S Kim; J-S Lee; Y-K Kang Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640
Authors: J Wei; Z Zou; X Qian; Y Ding; L Xie; J J Sanchez; Y Zhao; J Feng; Y Ling; Y Liu; L Yu; R Rosell; B Liu Journal: Br J Cancer Date: 2008-03-25 Impact factor: 7.640
Authors: Shruti Rao; Robert A Beckman; Shahla Riazi; Cinthya S Yabar; Simina M Boca; John L Marshall; Michael J Pishvaian; Jonathan R Brody; Subha Madhavan Journal: Oncotarget Date: 2017-06-06